Letter to the Editor
Benefit of Bet v 1 contiguous overlapping peptide immunotherapy persists during first follow-up season

https://doi.org/10.1016/j.jaci.2018.01.052Get rights and content

First page preview

First page preview
Click to open first page preview

References (7)

There are more references available in the full text version of this article.

Cited by (21)

  • Future Directions of Allergen Immunotherapy for Allergic Rhinitis: Experts’ Perspective

    2024, Journal of Allergy and Clinical Immunology: In Practice
  • TLR-5 ligand conjugated with Per a 10 and T cell peptides potentiates Treg/Th1 response through PI3K/mTOR axis

    2022, International Immunopharmacology
    Citation Excerpt :

    T cell epitopes in grass allergic patients demonstrated long term amelioration in rhino-conjunctivitis symptoms [4]. Similarly, Bet v 1 overlapping peptides induced blocking antibody levels upto two pollen seasons [5,6] Studies with Fel d 1 peptide immunotherapy demonstrated significant improvement in symptom scores, however, endpoint success results of Phase III clinical trial were unsatisfactory [7,8]. Adjuvants targeting toll like receptor signalling may augment efficacy of IT with allergen proteins and peptides.

  • Future of allergic rhinitis management

    2021, Annals of Allergy, Asthma and Immunology
    Citation Excerpt :

    The Bet v 1 COP 50 μg group had significantly improved allergic rhinitis combined with symptom and medication scores (RSMS) (mean RSMS improvement, 21%; adjusted mean difference from placebo of −0.200 with 95% confidence limit [CL], −0.375 to −0.025; P = .03), compared with the first season posttreatment. There was no difference in RSMS in the Bet v 1 COP 100 μg group (mean RSMS improvement, 18%; adjusted mean difference from placebo of −0.169 with 95% CL, −0.353 to 0.014; P = .07) between first and second seasons after treatment.44 PIT offers a shorter AIT schedule and may increase compliance for patients.

  • Persistence of the clinical effect of grass allergen peptide immunotherapy after the second and third grass pollen seasons

    2020, Journal of Allergy and Clinical Immunology
    Citation Excerpt :

    Similar reductions in symptoms were also observed with the 4x12Q4W dosing regimen at the 2-year follow-up. These findings are comparable with those of previous phase 2 trials, which reported a continued treatment benefit up to 2 years after the start of treatment for SPIREs derived from HDM and cat allergens9,10,12,13 and up to 1 year after treatment initiation for peptides derived from birch pollen.22,23 Consistent with the parent study, an apparent inverted dose-response threshold (based on cumulative exposure) was observed, with both 48-nmol regimens of grass allergen peptides outperforming the 96-nmol regimen at follow-up.

  • Allergen Extracts for In Vivo Diagnosis and Treatment of Allergy: Is There a Future?

    2018, Journal of Allergy and Clinical Immunology: In Practice
View all citing articles on Scopus

The study was supported by Anergis SA (Route de la Corniche 9B, 1066 Epalinges, Switzerland), the developer of Bet v 1 COP.

Disclosure of potential conflict of interest: F. de Blay reports grants from Stallergenes-Greer and Chiesi and personal fees from ALK, Mundipharma, and Novartis, during the conduct of the study; and is a board member for Stallergenes-Greer, Novartis, ALK, Mundipharma, Medapharma, Boehringer, and Teva. M. Jutel reports lecture fees from ALK-Abello; lecture fees, advisory board, and clinical investigator fees from Allergopharma; lecture fees and clinical investigator fees from Stallergenes; advisory board and clinical investigator fees from Anergis; advisory board fees from Biomay and UCB; and clinical investigator fees from HAL, Astra-Zeneka, GSK, Novartis, Teva, Vectura, Tekada, Roche, Janssen, Medimmune, Allergy Therapeutics, Circassia, Leti, and Chiesi. L. Jacobsen and M. Worm received money for consulting fees and study preparation from Anergis SA. L. Jacobsen received money for study preparation from Anergis SA. M. Worm was paid for consultancy outside of this research by Anergis SA. A. Kettner, G. DellaCorte, V. Charlon, C. Reymond, and K. Simonsen are employees of Anergis SA and have stock options with this company. V. Charlon received travel/accommodations/meeting expenses from Anergis SA unrelated to this research. F. Spertini has stock/stock options with Anergis SA; received support for travel to meetings for the study or other purposes from Anergis SA; has patents (planned, pending, or issued) and received royalties from CHUV, Lausanne, CH; and is a funder of the company Anergis SA, which supported this study.

These authors contributed equally to this work.

Gilles DellaCorte is currently at DELLMED Consulting, Ornex, France; Christophe Reymond is currently at Voisin Consulting Life Sciences, EPFL Innovation Park, Lausanne, Switzerland.

View full text